Kolltan Pharmaceuticals announces KTN0158 preclinical data at ESMO 2015

Substantial shrinkage in tumors and favorable results from nonclinical toxicology studies support IND filing in 2015. Initiation of Phase 1 clinical trial in GIST and other KIT-dependent solid tumors anticipated in 2016. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail